Femasys (NASDAQ:FEMY) vs. Replimune Group (NASDAQ:REPL) Financial Contrast

Femasys (NASDAQ:FEMY) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Earnings and Valuation

This table compares Femasys and Replimune Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.63 million	14.05	-$18.82 million	($0.86)	-0.82
Replimune Group	N/A	N/A	-$247.30 million	($3.24)	-1.39

Femasys has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Femasys and Replimune Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1	0	3	0	2.50
Replimune Group	3	6	2	0	1.91

Femasys currently has a consensus target price of $7.33, suggesting a potential upside of 943.00%. Replimune Group has a consensus target price of $6.50, suggesting a potential upside of 44.44%. Given Femasys’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Replimune Group.

Insider & Institutional Ownership

65.3% of Femasys shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 11.5% of Femasys shares are owned by insiders. Comparatively, 5.2% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Femasys and Replimune Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-1,113.72%	-713.74%	-152.60%
Replimune Group	N/A	-69.34%	-52.81%

Volatility & Risk

Femasys has a beta of -2.64, meaning that its share price is 364% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Summary

Femasys beats Replimune Group on 8 of the 13 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Replimune Group

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.